Gastrointestinal Disease and Pregnancy 

  • Author: Praveen K Roy, MD, AGAF; Chief Editor: David Chelmow, MD   more...
 
Updated: Mar 29, 2011
 

Overview

Gastrointestinal (GI) disorders represent some of the most frequent complaints during pregnancy. Some women have GI disorders that are unique to pregnancy. Other pregnant patients present with chronic GI disorders that require special consideration during pregnancy. Understanding the presentation and prevalence of various GI disorders is necessary to optimize care for these patients.[1, 2] This article focuses on common GI symptoms during pregnancy and the common GI diseases that can be challenging to manage during pregnancy.

For excellent patient education resources, visit eMedicine's Women's Health Center and Pregnancy and Reproduction Center. Also, see eMedicine's patient education articles Pregnancy and Pregnancy, Vomiting.

Next

Nausea and Vomiting

Nausea, with or without vomiting, is common in early pregnancy, usually self-limiting[3, 4] and occurs in 50-90% of pregnancies, whereas vomiting is an associated complaint in 25-55% of pregnancies. Risk factors for nausea in pregnancy include youth, obesity, first pregnancy, and smoking. Nausea tends to recur in subsequent pregnancies, though it may be shorter in duration.

Nausea in pregnancy occurs in 91% of women in the first trimester, generally in the first 6 to 8 weeks. In its mild form, nausea is known as morning sickness. The pathophysiology of this condition is debatable but has been attributed to hormonal fluctuations, GI motility disorders, and psychosocial factors. Persistence of nausea and vomiting into the second or third semester should prompt a search for other causes.

Other causes of nausea in pregnancy include urinary tract infections, gastroenteritis, peptic ulcer disease, pancreatitis, biliary tract disease, hepatitis, appendicitis, adrenal insufficiency, and increased intracranial pressure. In later pregnancy, considerations also include hydramnios, preeclampsia, and onset of labor.

Management of symptoms

The severity of symptoms dictates the approach to therapy in a pregnant patient with nausea. Mild symptoms can be managed by reassurance, avoidance of precipitating factors, and changes in diet (eg, smaller, more frequent meals; increased carbohydrate intake; low fat intake).

For more severe and intractable symptoms, pharmacotherapy with antiemetics can be offered. Meclizine (class B) or promethazine (class C) can be used. Adverse effects to the human fetus have not been reported, but meclizine and promethazine are not recommended for routine use in pregnancy.

Metoclopramide (class B) can be used in pregnancy. It has not been shown to induce teratogenic effects, but it crosses the placenta and produces substantial fetal blood alcohol effects.

Data on the harmful fetal effects of other antiemetics (eg, prochlorperazine [class C], diphenhydramine [class C], trimethobenzamide) preclude their use in pregnancy. Pyridoxine (vitamin B-6) is an alternative therapeutic agent in patients with severe nausea or vomiting.[5]

Prognosis

The prognosis for the mother and child is generally good. In fact, women with mild nausea and vomiting in pregnancy have better pregnancy outcomes compared with women without these symptoms.

Previous
Next

Hyperemesis Gravidarum

Hyperemesis gravidarum occurs in 3 to 10 cases per 1000 pregnancies and is characterized by intractable nausea and vomiting that occurs in early pregnancy, leading to fluid and electrolyte imbalances.[6, 7, 8] This condition may be considered to be at the severe end of the spectrum of nausea and vomiting in pregnancy, but the pathogenesis of hyperemesis gravidarum is poorly understood. Hormonal and psychologic factors may play a role. Risk factors associated with this condition include obesity, nulliparity, multiple gestations, and trophoblastic disease

Hyperemesis gravidarum occurs early in the first trimester, usually within weeks 4 through 10. Symptoms usually resolve by weeks 18 to 20. The symptoms of hyperemesis gravidarum include intractable vomiting; ptyalism; weight loss of >5% of body weight; possible malnutrition; abdominal pain (not common); possible ketosis, hypokalemia, and metabolic alkalosis; possible abnormal liver enzyme levels; and possible mild hyperthyroidism.

Management of metabolic imbalances, diet, and symptoms

Treatment of hyperemesis gravidarum focuses on replenishing fluids, electrolytes, vitamins, and minerals.[9] Thiamine supplementation is recommended for women who have had vomiting for longer than 3 weeks. It is important for the patient to avoid environmental triggers. In addition, patients should eat frequent, small, high-carbohydrate, low-fat meals to assist in managing this condition. Gut rest may be needed in some cases. Parenteral or enteral nutrition can be beneficial in some cases.

Antiemetics and pyridoxine can be used to alleviate nausea and vomiting. Corticosteroids have been tried in severe and refractory cases.

The prognosis with hyperemesis gravidarum is good. No differences in birth weight or birth defects have been observed in pregnancies affected by this condition.

Previous
Next

Gastroesophageal Reflux Disease

Gastroesophageal reflux disease (GERD), generally known as heartburn, is common in pregnancy and is experienced by 45-80% of pregnant women[10, 11, 12, 13, 14, 15, 16, 17, 18] Fifty-two percent of pregnant women first experience GERD in their first trimester, 24-40% experience it in their second trimester, and 9% in their third trimester.

Both mechanical and intrinsic factors are involved in GERD. Abnormal esophageal motility, decreased lower esophageal sphincter (LES) pressure,[19, 20, 21, 22, 23, 24, 25] and increased gastric pressure contribute to GERD in pregnancy. Increased intra-abdominal pressure from the gravid uterus and displacement of the LES also contribute to GERD in pregnancy.

Pregnant women with GERD present similarly to individuals in the general population; heartburn and regurgitation are the cardinal symptoms. The diagnostic evaluation consists of a thorough patient history and physical examination; diagnostic studies are rarely needed. Endoscopy may be indicated in patients with complications of GERD, and 24-hour ambulatory pH studies can be useful in patients with atypical presentations (eg, cough, wheezing, sore throat) and refractory symptoms.

Lifestyle modifications and pharmacologic management

Lifestyle modifications are the first line of management in pregnant women with GERD. To reduce symptoms and increase comfort related to GERD, advise pregnant patients to elevate the head of the bed; avoid bending or stooping positions; eat small, frequent meals; and refrain from ingesting food (except liquids) within 3 hours of bedtime.

With regard to medications, antacids or sucralfate are safe in pregnancy, because they are not systemically absorbed. Note, however, that antacids may interfere with iron absorption.

Histamine 2 (H2) blockers are preferred over proton pump inhibitors (PPIs), because more data are available on the safety of H2-blocker use in pregnancy. However, a recent large cohort study found that exposure to PPIs in the first trimester of pregnancy was not associated with increased risk of birth defects.[26] Cimetidine, ranitidine, and famotidine can be used in pregnancy (class B drugs), but they can cross the placental barrier. Lansoprazole is the preferred proton pump inhibitor in pregnancy (class B).

The outcome for pregnant patients with GERD is good. However, this condition tends to recur with subsequent pregnancies.

Previous
Next

Gallstones

Pregnancy is associated with an increased risk of gallstone formation, which in turn is an important cause of pancreatitis in pregnancy. Cholecystectomy is the second most common nonobstetric surgical procedure in pregnancy, exceeded only by appendectomy.[27]

The exact mechanism of gallstone formation in pregnancy is not known, but 31% of women develop biliary sludge during pregnancy, and 2% develop new gallstones. The risk for these conditions is highest in the second or third trimester and during the postpartum period. Possible contributing factors are an increased lithogenicity of bile, increased stasis of bile, and decreased gall bladder emptying.

Pregnant women with cholelithiasis may present with right upper quadrant or epigastric pain, fever, vomiting, jaundice, tenderness in the right upper quadrant that may be difficult to elicit because of an enlarged uterus, and/or pancreatitis.[28]

Medical and surgical management

Severe biliary colic can be managed conservatively with hydration, narcotics, antibiotics, and dietary modifications. Endoscopic retrograde cholangiopancreatography (ERCP) may be needed in cases of cholangitis, biliary obstruction, or pancreatitis.

Cholecystectomy is indicated in the presence of persistent or recurrent symptoms, significant nutritional compromise, and weight loss. This procedure is required in less than 0.1% of cases. The second trimester is the best period for surgery in affected pregnant women.

Previous
Next

Peptic Ulcer Disease

Peptic ulcer disease (PUD) is uncommon during pregnancy, with a reported incidence rate of 0.005%, although this is probably underestimated. PUD is believed to improve during pregnancy as a result of decreased gastric acid secretion. Risk factors for PUD in pregnancy include smoking, alcoholism, stress, socioeconomic status, and previous history of PUD or Helicobacter pylori gastritis. Nonsteroidal medications are not a common risk factor for PUD in pregnancy.

The clinical features of this condition in pregnant women are similar to those in the nonpregnant state. Symptoms include dyspepsia, epigastric pain, nausea, vomiting, and heartburn. GI bleeding and perforation are rare complications of PUD in pregnancy. PUD does not cause increased maternal or fetal morbidity and mortality.

Pharmacologic management

H2-receptor antagonists (eg, cimetidine, ranitidine, famotidine) are the first choices of treatment for peptic ulcer disease. Treatment for Helicobacter pylori gastritis should be initiated after the pregnancy and breastfeeding periods are complete, because some of the recommended medications are relatively contraindicated in pregnancy. Lansoprazole has been reported to be safe in pregnancy.

Previous
Next

Diarrhea

Diarrhea occurs in up to 34% of pregnant women, and its causes in pregnancy mirror those of the nonpregnant state, with the most common being infectious agents (eg, Salmonella, Shigella, and Campylobacter species; Escherichia coli; protozoans; viruses). Food poisoning, medications, and irritable bowel syndrome are other common causes. Exacerbations of inflammatory bowel disease can also occur in pregnancy.

Evaluation and management

Conduct a routine laboratory evaluation with stool studies for bacterial culture, ova, parasites, fecal leukocytes, and stool assay for Clostridium difficile infection. For persistent diarrhea, flexible sigmoidoscopy can be performed, as it is safe in pregnancy.

Conservative management is the mainstay of treatment for diarrhea in pregnancy. Administer fluid replacement, and administer medications to control the diarrhea, if needed. Nonsystemic medications should be tried first, and the underlying cause should be treated.

Treat patients with irritable bowel syndrome by instituting a high-fiber diet and administering stool-bulking agents. Avoid antidepressants. Anticholinergics/antispasmodics are not recommended.

Previous
Next

Constipation

The incidence rate of constipation in pregnancy is 11-38%.[29, 30] The etiology is multifactorial, with decreased small bowel motility, decreased motilin level, decreased colonic motility, increased absorption of water, and iron supplementation as possible contributory factors.

Evaluation and management

Extensive clinical evaluation is seldom warranted for constipation during pregnancy. The evaluation should include a careful history, including the presence of preexisting constipation, dietary habits, current medications, and the use of laxatives. Perform a digital rectal examination to exclude fecal impaction.

The results of blood studies can be useful to exclude hypothyroidism, diabetes mellitus, hypercalcemia, and hypokalemia as possible causes. If rectal bleeding is present, anoscopy or flexible sigmoidoscopy can be performed to exclude anorectal lesions.[31, 32, 33]

Conservative treatment is the mainstay of therapy for diarrhea in pregnancy and includes the following instituting dietary changes, increasing physical activity, performing Kegel exercises (may be useful), and using bulking agents (eg, psyllium, safe in pregnancy).

Few data are available on the safety and efficacy of medications in pregnancy. Stool softeners such as sodium docusate are probably safe. Stimulant laxatives are probably safe for intermittent use, but these agents should not be used regularly. Castor oil and mineral oil should not used in pregnancy.

Previous
 
Contributor Information and Disclosures
Author

Praveen K Roy, MD, AGAF  Gastroenterologist, Oschner Clinic Foundation; Clinical Assistant Professor of Medicine, University of New Mexico School of Medicine; Comments and Criticisms Editor, Cochrane Colorectal Cancer Group; Adjunct Associate Research Scientist, Lovelace Respiratory Research Institute; Editor-in-Chief, The Internet Journal of Gasteroenterology; Editorial Board, Signal Transduction Insights; Editorial Board, The Internet Journal of Epidemiology; Editorial Board, Gastrointestinal Endoscopy Review Letter

Praveen K Roy, MD, AGAF is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, and American Society of Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Coauthor(s)

Abhishek Choudhary, MD  Resident Physician, Department of Internal Medicine, University Hospital of Missouri-Columbia

Abhishek Choudhary, MD is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

Mohamed Othman, MD  Resident Physician, Department of Internal Medicine, University of New Mexico School of Medicine

Disclosure: Nothing to disclose.

Homayoun Shojamanesh, MD  Former Fellow, Digestive Diseases Branch, National Institutes of Health

Homayoun Shojamanesh, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Jack Bragg, DO  Associate Professor, Department of Clinical Medicine, University of Missouri School of Medicine

Jack Bragg, DO is a member of the following medical societies: American College of Osteopathic Internists and American Osteopathic Association

Disclosure: Nothing to disclose.

Gautam Dehadrai, MD  Department Chair, Section Chief, Department of Interventional Radiology, Norman Regional Hospital

Gautam Dehadrai, MD is a member of the following medical societies: American College of Radiology, Medical Council of India, and Radiological Society of North America

Disclosure: Nothing to disclose.

Showkat Bashir, MD  Assistant Professor, Department of Medicine, Division of Gastroenterology, George Washington University, Washington, DC

Showkat Bashir, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, and American Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Ann Ouyang, MBBS  Professor, Department of Internal Medicine, Pennsylvania State University College of Medicine; Attending Physician, Division of Gastroenterology and Hepatology, Milton S Hershey Medical Center

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

Alex J Mechaber, MD, FACP  Senior Associate Dean for Undergraduate Medical Education, Associate Professor of Medicine, University of Miami Miller School of Medicine

Alex J Mechaber, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, and Society of General Internal Medicine

Disclosure: Nothing to disclose.

Chief Editor

David Chelmow, MD  Leo J Dunn Distinguished Professor and Chair, Department of Obstetrics and Gynecology, Virginia Commonwealth University Medical Center

David Chelmow, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Medical Association, Association of Professors of Gynecology and Obstetrics, Massachusetts Medical Society, Phi Beta Kappa, Sigma Xi, Society for Gynecologic Investigation, and Society for Medical Decision Making

Disclosure: Nothing to disclose.

References
  1. Atlay RD, Weekes AR. The treatment of gastrointestinal disease in pregnancy. Clin Obstet Gynaecol. Jun 1986;13(2):335-47. [Medline].

  2. Knudsen A, Lebech M, Hansen M. Upper gastrointestinal symptoms in the third trimester of the normal pregnancy. Eur J Obstet Gynecol Reprod Biol. May 1995;60(1):29-33. [Medline].

  3. Koch KL. Gastrointestinal factors in nausea and vomiting of pregnancy. Am J Obstet Gynecol. May 2002;186(5 Suppl Understanding):S198-203. [Medline].

  4. Koch KL, Frissora CL. Nausea and vomiting during pregnancy. Gastroenterol Clin North Am. Mar 2003;32(1):201-34, vi. [Medline].

  5. Flake ZA, Scalley RD, Bailey AG. Practical selection of antiemetics. Am Fam Physician. Mar 1 2004;69(5):1169-74. [Medline].

  6. Abell TL, Riely CA. Hyperemesis gravidarum. Gastroenterol Clin North Am. Dec 1992;21(4):835-49. [Medline].

  7. Eliakim R, Abulafia O, Sherer DM. Hyperemesis gravidarum: a current review. Am J Perinatol. 2000;17(4):207-18. [Medline].

  8. Kuscu NK, Koyuncu F. Hyperemesis gravidarum: current concepts and management. Postgrad Med J. Feb 2002;78(916):76-9. [Medline]. [Full Text].

  9. Pearce CB, Collett J, Goggin PM, Duncan HD. Enteral nutrition by nasojejunal tube in hyperemesis gravidarum. Clin Nutr. Oct 2001;20(5):461-4. [Medline].

  10. Lind JF, Smith AM, McIver DK, Coopland AT, Crispin JS. Heartburn in pregnancy--a manometric study. Can Med Assoc J. Mar 23 1968;98(12):571-4. [Medline]. [Full Text].

  11. Briggs DW, Hart DM. Heartburn of pregnancy. A continuation study. Br J Clin Pract. Apr 1972;26(4):167-9. [Medline].

  12. Bassey OO. Pregnancy heartburn in Nigerians and Caucasians with theories about aetiology based on manometric recordings from the oesophagus and stomach. Br J Obstet Gynaecol. Jun 1977;84(6):439-43. [Medline].

  13. Marrero JM, Goggin PM, de Caestecker JS, Pearce JM, Maxwell JD. Determinants of pregnancy heartburn. Br J Obstet Gynaecol. Sep 1992;99(9):731-4. [Medline].

  14. Broussard CN, Richter JE. Treating gastro-oesophageal reflux disease during pregnancy and lactation: what are the safest therapy options?. Drug Saf. Oct 1998;19(4):325-37. [Medline].

  15. Ho KY, Kang JY, Viegas OA. Symptomatic gastro-oesophageal reflux in pregnancy: a prospective study among Singaporean women. J Gastroenterol Hepatol. Oct 1998;13(10):1020-6. [Medline].

  16. Richter JE. Gastroesophageal reflux disease during pregnancy. Gastroenterol Clin North Am. Mar 2003;32(1):235-61. [Medline].

  17. Baron TH, Richter JE. Gastroesophageal reflux disease in pregnancy. Gastroenterol Clin North Am. Dec 1992;21(4):777-91. [Medline].

  18. [Best Evidence] Dowswell T, Neilson JP. Interventions for heartburn in pregnancy. Cochrane Database Syst Rev. Oct 8 2008;CD007065. [Medline].

  19. Fisher RS, Roberts GS, Grabowski CJ, Cohen S. Inhibition of lower esophageal sphincter circular muscle by female sex hormones. Am J Physiol. Mar 1978;234(3):E243-7. [Medline].

  20. Fisher RS, Roberts GS, Grabowski CJ, Cohen S. Altered lower esophageal sphincter function during early pregnancy. Gastroenterology. Jun 1978;74(6):1233-7. [Medline].

  21. Dodds WJ, Dent J, Hogan WJ. Pregnancy and the lower esophageal sphincter. Gastroenterology. Jun 1978;74(6):1334-6. [Medline].

  22. Brock-Utne JG, Dow TG, Welman S, Dimopoulos GE, Moshal MG. The effect of metoclopramide on the lower oesophageal sphincter in late pregnancy. Anaesth Intensive Care. Feb 1978;6(1):26-9. [Medline].

  23. Brock-Utne JG, Dow TG, Dimopoulos GE, Welman S, Downing JW, Moshal MG. Gastric and lower oesophageal sphincter (LOS) pressures in early pregnancy. Br J Anaesth. Apr 1981;53(4):381-4. [Medline].

  24. Dow TG, Brock-Utne JG, Rubin J, Welman S, Dimopoulos GE, Moshal MG. The effect of atropine on the lower esophageal sphincter in late pregnancy. Obstet Gynecol. Apr 1978;51(4):426-30. [Medline].

  25. Brock-Utne JG, Downing JW, Dimopoulos GE, Rubin J, Moshal MG. Effect of domperidone on lower esophageal sphincter tone in late pregnancy. Anesthesiology. Apr 1980;52(4):321-3. [Medline].

  26. Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med. Nov 25 2010;363(22):2114-23. [Medline].

  27. Date RS, Kaushal M, Ramesh A. A review of the management of gallstone disease and its complications in pregnancy. Am J Surg. Oct 2008;196(4):599-608. [Medline].

  28. [Best Evidence] Eddy JJ, Gideonsen MD, Song JY, Grobman WA, O'Halloran P. Pancreatitis in pregnancy. Obstet Gynecol. Nov 2008;112(5):1075-81. [Medline]. [Full Text].

  29. Tytgat GN, Heading RC, Müller-Lissner S, Kamm MA, Schölmerich J, Berstad A, et al. Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meeting. Aliment Pharmacol Ther. Aug 1 2003;18(3):291-301. [Medline].

  30. Jewell DJ, Young G. Interventions for treating constipation in pregnancy. Cochrane Database Syst Rev. 2001;CD001142. [Medline].

  31. Chaliha C, Sultan AH, Bland JM, Monga AK, Stanton SL. Anal function: effect of pregnancy and delivery. Am J Obstet Gynecol. Aug 2001;185(2):427-32. [Medline].

  32. Martínez Hernández Magro P, Villanueva Sáenz E, Jaime Zavala M, Sandoval Munro RD, Rocha Ramírez JL. Endoanal sonography in assessment of fecal incontinence following obstetric trauma. Ultrasound Obstet Gynecol. Dec 2003;22(6):616-21. [Medline].

  33. O'Boyle AL, O'Boyle JD, Magann EF, Rieg TS, Morrison JC, Davis GD. Anorectal symptoms in pregnancy and the postpartum period. J Reprod Med. Mar 2008;53(3):151-4. [Medline].

  34. Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. Nov 2010;96(22):1821-5. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.